|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2400081235 |
|
最近更新日期: Date of Last Refreshed on: |
2024-02-27 09:35:15 |
|
注册时间: Date of Registration: |
2024-02-27 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
研究分析急性肺损伤代谢物的改变并筛选鉴定急性肺损伤诊断生物标志 |
|
Public title: |
Study and analyze changes in metabolites of acute lung injury and screen and identify diagnostic biomarkers for acute lung injury |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
基于代谢组学的人体临床标本质谱检测预测患者急性肺损伤(ALI)——一项前瞻性多中心观察性研究 |
|
Scientific title: |
Metabolomics based mass spectrometry detection of human clinical specimens for predicting acute lung injury (ALI) in patients: a prospective multicenter observational study |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
吴文博 |
研究负责人: |
路国涛 |
|
Applicant: |
Wu Wenbo |
Study leader: |
Lu Guotao |
|
申请注册联系人电话: Applicant telephone: |
+86 138 1528 0867 |
研究负责人电话: Study leader's telephone: |
+86 151 6188 9176 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
a771923084@163.com |
研究负责人电子邮件: Study leader's E-mail: |
gtlu@yzu.edu.cn |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
江苏省扬州市邗江区汉江中路368号扬州大学附属医院 |
研究负责人通讯地址: |
江苏省扬州市邗江区汉江中路368号扬州大学附属医院 |
|
Applicant address: |
Affiliated Hospital of Yangzhou University, No. 368, Hanjiang Middle Road, Hanjiang District, Yangzhou City, Jiangsu Province |
Study leader's address: |
Affiliated Hospital of Yangzhou University, No. 368, Hanjiang Middle Road, Hanjiang District, Yangzhou City, Jiangsu Province |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
扬州大学附属医院 |
||
|
Applicant's institution: |
Affiliated Hospital of Yangzhou University |
||
|
研究负责人所在单位: |
扬州大学附属医院 |
||
|
Affiliation of the Leader: |
Affiliated Hospital of Yangzhou University |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2023-YKL06-(课19) |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
扬州大学附属医院伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of Affiliated Hospital of Yangzhou University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2023-06-30 00:00:00 |
||
|
伦理委员会联系人: |
许老师 |
||
|
Contact Name of the ethic committee: |
Teacher Xu |
||
|
伦理委员会联系地址: |
江苏省扬州市邗江区汉江中路368号扬州大学附属医院 |
||
|
Contact Address of the ethic committee: |
Affiliated Hospital of Yangzhou University, No. 368, Hanjiang Middle Road, Hanjiang District, Yangzhou City, Jiangsu Province |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 159 5068 2071 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
扬州大学附属医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Affiliated Hospital of Yangzhou University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
江苏省扬州市邗江区汉江中路368号扬州大学附属医院 |
||||||||||||||||||||||
|
Primary sponsor's address: |
Affiliated Hospital of Yangzhou University, No. 368, Hanjiang Middle Road, Hanjiang District, Yangzhou City, Jiangsu Province |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
自筹资金 |
||||||||||||||||||||||
|
Source(s) of funding: |
self-raised funds |
||||||||||||||||||||||
|
Target disease: |
Lung injury |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
诊断试验新技术临床试验 | ||||||||||||||||||||||
|
Study phase: |
Diagnostic New Technique Clincal Study |
||||||||||||||||||||||
|
研究设计: |
横断面 |
||||||||||||||||||||||
|
Study design: |
Cross-sectional |
||||||||||||||||||||||
|
研究目的: |
主要目的是通过基于代谢组学的人体临床标本质谱检测分析急性肺损伤患者代谢物改变并筛选鉴定急性肺损伤诊断生物标志 |
||||||||||||||||||||||
|
Objectives of Study: |
The main purpose is to analyze metabolic changes in acute lung injury patients through metabolomics based mass spectrometry of human clinical specimens, and screen and identify diagnostic biomarkers for acute lung injury |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
(1)年龄为18岁-80岁,性别不限;(2) 有肺损伤因素:严重肺部感染,胃内容物吸入,肺挫伤,吸入有毒气体,淹溺、氧中毒、严重感染,严重的非胸部创伤,急性重症胰腺炎,大量输血,体外循环,弥漫性血管内凝血等;(3) 有自主意识,能独立判断;(4)患者或其家属知晓本研究,已签署同意书。 |
||||||||||||||||||||||
|
Inclusion criteria |
(1) Age range from 18 to 80 years old, regardless of gender; (2) Lung injury factors: severe lung infection, inhalation of stomach contents, Pulmonary contusion, inhalation of toxic gases, drowning, oxygen poisoning, severe infection, severe non Chest injury, acute severe pancreatitis, massive blood transfusion, extracorporeal circulation, disseminated intravascular coagulation, etc; (3) Having independent consciousness and the ability to make independent judgments; (4) The patient or their family members are aware of this study and have signed a consent form. |
||||||||||||||||||||||
|
排除标准: |
(1)无法良好理解、不能耐受或配合临床标本收集的患者;(2)伴随有精神疾病患者; (3)临床资料不完整的患者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
(1) Patients who are unable to understand, tolerate, or cooperate with clinical specimen collection; (2) Accompanying patients with mental illness; (3) Patients with incomplete clinical data. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2023-06-30 00:00:00至 To 2026-06-30 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2023-10-11 00:00:00 至 To 2026-06-30 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
none |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
|
|
Blinding: |
|
是否共享原始数据: IPD sharing |
No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
论文发表后使用数据平台 ResMan(www.medresman.org) |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
After publishing the paper, use the data platform ResMan (www.medrescman. org) |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
一.病例记录表,二.电子采集和管理系统 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
1 Case Record Form, 2 Electronic Collection and Management System |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |